Automation is key to saving lives Cell and Gene Therapy Processing?Personalised tumour treatments are expensive. This particularly applies to individual cancer therapies based on gene-modified T cells. Currently, they are produced manually … more ➔
Advancing cancer immunotherapySingle cell multiomics has the capacity to address key challenges to developing cell and gene therapies, specifically CAR T-cell therapies. Hear how leading cancer immunotherapy researchers are using … more ➔
BioSpain 2021, showcasing Spanish biotech... The largest biotech event organised by a national bioindustry association (AseBio) in Europe and one of the biggest in the world will take place from 27 September to 1 October. To be held in Pamplona-Iruña, … more ➔
Managing risks and finding opportunities t...By applying the expertise, best practice, and emerging technologies of the logistics industry, biotech not only prevents the missteps that can destroy its products, it can also capitalise on opportunities … more ➔
Medical Cannabis in Europe – the nex...The cannabis industry has established its first footholds in Europe over the past six years – but what comes next? European Biotechnology invited US-German American consultant, entrepreneur and author … more ➔
Tough times for cancer cell therapiesSo far, no gene and cell therapies have been approved to treat solid tumours. European Biotechnology spoke with Karen Miller, SVP Pipeline Research at Adaptimmune plc, about promising candidates, and … more ➔
Red blood cell contaminants from source ma...Isolating cells from whole blood or LRS cones carries the risk of red blood cell (RBC) contamination, which can have deleterious effects on downstream cell cultures. more ➔
Trading medical cannabis in EuropeThe regulatory situation regarding the trade of medicinal cannabis currently varies enormously from country to country within the European Union. Unfortunately, there is still no full regulatory harmonization … more ➔
Advancing protein production with Pichia p...Effective bioprocess development starts with the targeted and time-saving generation of high-productivity strains already considering economic target values and regulatory requirements. The UNLOCK PICHIA … more ➔
AAV vectors from a CDMO that cares about S...The future of AAV vector-based therapies holds great promise if manufacturers can cope with the demand. While in-house manufacturing may be an option for some companies, partnering with a CDMO can be … more ➔
